Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Bowel obstruction medical therapy

Introduction

Overview

Overview

The mainstay treatment of bowel obstruction is surgical and non-operative management. The role of medical therapy is supportive and is limited by palliative pain management in cancer patients, fluid and electrolyte replenishment, decreasing abdominal distension, peritumoral edema, intraluminal secretions, peristaltic movements, and control of nausea and vomiting.

Medical Therapy

Medical Therapy

The mainstay treatment of bowel obstruction is surgical and non-operative management. The role of medical therapy is supportive and is limited by control of vomiting and nausea, fluid and electrolyte replenishment, and palliative pain management in cancer patients. Glucocorticoids, octreotide and anticholinergic agents can be used to decrease abdominal distension, peritumoral edema, intraluminal secretions, and peristaltic movements. Antibiotics also play a role in treating infections but are not routinely recommended.[1][2][3][4][5][6][7][8][9]

  • 1 Antiemetics
    • 1.1 Antiemetics in cancer patients
      • 1.1.1 Adult
      • 1.1.2 Antiemetics in non-cancer patients
        • Preferred regimen (1): Promethazine 12.5-25 mg q4 – 6h PRN or PO, alternatively 12.5-25 mg q4 – 6h IV or IM
        • Preferred regimen (2): Ondansetron 4 – 8 mg q8-12hr PO or IV
      • 1.1.3 Pediatric
        • 1.1.3.1 Children 1 month – 12 years of age
        • 1.1.3.1 Children < 2 years of age
        • 1.1.3.2 Children > 2 years of age
          • Preferred regimen (1): Promethazine 0.25-1 mg/kg PO/PR q4-6hr; not > 25 mg
        • 1.1.3.2 Children > 12 years of age
          • Preferred regimen (1): Ondansetron 4 mg IV/IM or 16 mg PO 1 hr
  • 2 Fluid and electrolyte replacement
    • 2.1 Fluid replacement
      Note (1): Replacement is only necessary if deficit continues for >48h, or in excess of 2L in 24h
  • 3 Pain management in cancer/non-cancer patients
    • 3.1 Non-opioids
      • 3.1.1 Adult
        • Preferred regimen (1): Acetaminophen 325โ€“1000 mg PO q4โ€“6h PRN
        • Alternative regimen (2): Aspirin 325โ€“650 mg PO q4h PRN
        • Alternative regimen (3): Diclofenac 50 mg PO BID-TID
        • Alternative regimen (3): Etodolac 200โ€“400 mg PO q6โ€“8h
        • Alternative regimen (4): Ibuprofen 400โ€“600 mg POq 4โ€“6h PRN
        • Alternative regimen (5): Indomethacin 25โ€“50 mg PO TID
        • Alternative regimen (6): Ketoprofen 25โ€“50 mg PO q6hโ€“q8h
        • Alternative regimen (7): Ketorolac 10 mg PO q4โ€“6h PRN or 30 mg IV/IM q6h
        • Alternative regimen (8): Meclofenamate 50โ€“100 mg PO q4โ€“6h PRN
        • Alternative regimen (9): Mefenamic acid 250 mg PO q4โ€“6 PRN
        • Alternative regimen (10): Meloxicam 7.5โ€“15 mg PO once daily
        • Alternative regimen (11): Nabumetone 100โ€“2000 mg once daily
        • Alternative regimen (12): Naproxen 250โ€“500 mg PO BID
        • Alternative regimen (13): Oxaprozin 1200 mg PO once daily
        • Alternative regimen (14): Piroxicam 20 mg PO once daily
        • Alternative regimen (15): Sulindac 150โ€“200 mg PO BID
        • Alternative regimen (16): Tolmetin 200โ€“600 mg PO BID-TID
        • Alternative regimen (17): Tramadol 50โ€“100 mg PO q4โ€“6h PRN; 100 โ€“ 300 mg QD for SR
        • Alternative regimen (18): Celecoxib 200 mg PO BID
    • 3.2 Opioids
      • 3.2.1 Adult
        • Preferred regimen (1): Morphine sulfate 10โ€“30 mg q3โ€“4h PO
        • Alternative regimen (1.2): Rectal suppository; 10โ€“20 mg q4h
        • Alternative regimen (1.3): PRN; 2.5โ€“10 mg q2โ€“6h
        • Alternative regimen (1.4): Epidural; 3โ€“5 mg once, then 0.1โ€“0.7 mg/hr
        • Alternative regimen (1.5): Intrathecal; start 100:1 IT-to-IV, then titrate to pain
        • Alternative regimen (1.6): Controlled release tab 15โ€“30 mg q8โ€“12h
        • Alternative regimen (1.7): Sustained release tab 15โ€“30 mg q8โ€“12h
        • Alternative regimen (1.8): Extended release capsule 20 mg q24h, may increase by 20 mg increments every other day
        • Alternative regimen (1.9): Extended release capsule 30 mg q24h, may increase by 30 mg increments q4days (max 1600 mg/d)
        • Alternative regimen (2): Codeine 15โ€“60 mg q4โ€“6h (max 60 mg/d)
        • Alternative regimen (3): Dilaudid 2โ€“8 mg q3-4h for PO and PR
        • Alternative regimen (4): Roxycodone 5โ€“30 mg q4h
        • Alternative regimen (5): Oxycontin 10โ€“160 mg q12h
        • Alternative regimen (6): Opana 5โ€“10 mg q4โ€“6h
        • Alternative regimen (7): Opana extended release 5โ€“40 mg q12h
        • Alternative regimen (8): Propoxyphene HCl 65 mg q4h (max 390 mg/24h)
        • Alternative regimen (9): Methadone 2.5โ€“10 mg q3-6h
          Note (1): Has very long half-life (8โ€“60 hours)
        • Alternative regimen (10): Meperidine 50โ€“150 mg q3โ€“4h
          Note (2): Decrease dose if given IV, administer slow or via PCA. Not recommended for chronic use.
        • Alternative regimen (11): Fentanyl 25โ€“100 mcg q1โ€“2h or 0.5โ€“1.5 mcg/kg/hr IV infusion via PCA
        • Alternative regimen (12): Actiq; start with 200 mcg for breakthrough pain episodes, then titrate to pain
        • Alternative regimen (13): Duragesic 25 mcg/h q72hr, may increase q3โ€“6days
  • 4 Anti-edema
    • 4.1 Glucocorticoids
      • 4.1.1 Adult
          • Preferred regimen (1): Dexamethasone 6 – 16 mg IV or SC daily for 3 – 5 days, not > 7 days
          • Alternative regimen (1): Prednisolone 15 – 50 mg IV or SC daily for 3 – 5 days, not > 7 days
  • 5 Anti-secretion, anti-peristaltic, and anti-emetic
  • 6 Infection management
    • 6.1 Antibiotics
      • 6.1.1 Adult
        • Preferred regimen (1): Cefazolin 2 g IV q12hr severe infection, 3 g IV q12hr life-threatening infection
        • Alternative regimen (2): Cefoxitin 1 g IV q4hr or 2 g IV q6-8hr severe infection, 6-8 g/day maximum in life threatening
        • Alternative regimen (3): Cefotetan 2 g IV q12hr severe infection, 3 g IV q12hr life-threatening infection
        • Alternative regimen (4): Cefuroxime 1.5 g IV/IM q8hr severe infection; q6hr in life-threatening circumstances
        • Alternative regimen (5): Meropenem 1 g IV q8hr severe infection; not > 2 g IV q8hr
      • 6.1.2 Pediatric
        • 6.1.2.1 Neonate < 7 days old
          • Preferred regimen (1): Cefazolin 40 mg/kg q12h IV or IM daily divided
          • Alternative regimen (2): Cefuroxime 100 mg/kg q12h IV or IM daily divided
          • Alternative regimen (3): Meropenem 20 mg/kg q8h IV; not > 1 g q8h
        • 6.1.2.2 Infants > 7 days old
          • Preferred regimen (1): Cefazolin 25-100 mg/kg q6-8h IV or IM daily divided; not > 6 g daily
          • Alternative regimen (2): Cefoxitin 80-160 mg/kg q4-6h IV daily divided
          • Alternative regimen (3): Cefotetan 40-80 mg/kg q12h IV or IM daily divided
          • Alternative regimen (4): Cefuroxime 150 mg/kg q8h IV or IM daily divided
          • Alternative regimen (5): Meropenem 20 mg/kg q8h IV; not > 1 g q8h
  • 7 Prokinetics
    • Preferred regimen (1): Metoclopramide 10 mg q4h SC or 60 – 200 mg SC daily continuous injection
      • Note (1): Contraindicated in complete bowel obstruction
    • Alternative regimen (2): Domperidone 10 mg PO QID
References

References

  1. โ†‘ Sagar PM, MacFie J, Sedman P, May J, Mancey-Jones B, Johnstone D (1995). “Intestinal obstruction promotes gut translocation of bacteria”. Dis. Colon Rectum. 38 (6): 640โ€“4. PMIDย 7774478.
  2. โ†‘ LE QUESNE LP (1955). “Fluid balance in intestinal obstruction”. Postgrad Med J. 31 (355): 227โ€“33. PMCย 2500705. PMIDย 14371195.
  3. โ†‘ Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J (1994). “Palliation of malignant intestinal obstruction using octreotide”. Eur. J. Cancer. 30A (1): 28โ€“30. PMIDย 7511400.
  4. โ†‘ Spears H, Petrelli NJ, Herrera L, Mittelman A (1988). “Treatment of bowel obstruction after operation for colorectal carcinoma”. Am. J. Surg. 155 (3): 383โ€“6. PMIDย 3344898.
  5. โ†‘ Ripamonti CI, Easson AM, Gerdes H (2008). “Management of malignant bowel obstruction”. Eur. J. Cancer. 44 (8): 1105โ€“15. doi:10.1016/j.ejca.2008.02.028. PMIDย 18359221.
  6. โ†‘ Blair SL, Chu DZ, Schwarz RE (2001). “Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer”. Ann. Surg. Oncol. 8 (8): 632โ€“7. PMIDย 11569777.
  7. โ†‘ Higashi H, Shida H, Ban K, Yamagata S, Masuda K, Imanari T, Yamamoto T (2003). “Factors affecting successful palliative surgery for malignant bowel obstruction due to peritoneal dissemination from colorectal cancer”. Jpn. J. Clin. Oncol. 33 (7): 357โ€“9. PMIDย 12949063.
  8. โ†‘ Frank C (1997). “Medical management of intestinal obstruction in terminal care”. Can Fam Physician. 43: 259โ€“65. PMCย 2255220. PMIDย 9040913.
  9. โ†‘ Mercadante S, Ferrera P, Villari P, Marrazzo A (2004). “Aggressive pharmacological treatment for reversing malignant bowel obstruction”. J Pain Symptom Manage. 28 (4): 412โ€“6. doi:10.1016/j.jpainsymman.2004.01.007. PMIDย 15471659.

โ€‹โ€‹


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]